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Evaluating whether an intervention works when trialled in groups of individuals can pose complex challenges for
clinical research. Cluster randomised controlled trials involve the random allocation of groups or clusters of
individuals to receive an intervention, and they are commonly used in global health research. In this paper, we
describe the potential reasons for the increasing popularity of cluster trials in low-income and middle-income
countries. We also draw on key areas of global health research for an assessment of common trial planning practices,
and we address their methodological shortcomings and pitfalls. Lastly, we discuss alternative approaches for
population-level intervention trials that could be useful for research undertaken in low-income and middle-income
countries for situations in which the use of cluster randomisation might not be appropriate.

Introduction
Use of robust randomised clinical trial (RCT) evaluation
is crucial to determine which interventions would be
useful for public health or clinical care.1,2 Certain
interventions are delivered at a population level or at a
group level, and these interventions can result in
changes to group behaviours, leading to large scale
population-level effects.3 The cluster RCT design (herein,
cluster trial) is a specific trial design that is used to
evaluate interventions delivered at a group level.4 In
cluster trials, whole groups of structured collections of
individuals or health system service delivery platforms,
such as facilities, are randomly assigned to receive
interventions, and these groups are referred to as
clusters. Examples of clusters include communities,
health clinics, or schools. In contrast to the individual
RCT, in which the group allocation of interventions is
determined by randomisation of individual participants,
cluster trials randomly assign interventions to a whole
cluster of individuals. Interventions themselves can be
administered at a cluster level (eg, mosquito egg traps5)
or at an individual level (eg, vaccinations6). In cluster
trials, outcomes can be measured at a cluster level6 or at
an individual level.7
There is an increasing popularity of the use of cluster
trials in low-income and middle-income countries
(LMICs).8 There have been many successful high-profile
trials that have used a cluster trial design, and many of
the design features of cluster trials lend themselves well
to priority areas of research set in LMICs. Despite the
increasing use of this design, there can be methodological
and interpretational challenges. Cluster trials are
complex due to the interplay between the similarities of
individual participants within a cluster and the
differences between clusters.9,10 Because outcomes of
individuals within the same cluster are correlated,
standard methods for design and analysis of individual
RCTs do not suffice for cluster trials. Furthermore,
www.thelancet.com/lancetgh Vol 9 May 2021

because special considerations are required when
designing and analysing cluster trials, there have been
great efforts towards unifying and improving the
standards of the design and analysis interpretation of
cluster trials.9,11 However, some evaluations have
identified several design and interpretational challenges
to cluster trials that often arise due to inadequate
planning.12–14
In this third paper of the Series, we first discuss
the attributes of cluster trials in the context of global
health research, followed by specific challenges that
are associated with planning and implementing such
attributes in LMICs. We then draw on examples of
Key messages
• When interventions can be delivered at the individual level,
there should be clear scientific justifications for cluster
randomisation. Cluster trials are ideal for evaluating
interventions that can only be delivered at the level of
clusters or interventions that have shown to be effective
under controlled conditions in individually randomised
clinical trials that require further evaluation of whether
they work at scale. In appropriate situations, cluster trials
can be better tailored for implementation science than
individually randomised controlled trials.
• During the trial planning stage, it is difficult to estimate
clustering effects (eg, intracluster correlation) and other
key assumptions required in traditional trial designs (eg,
event rates and treatment effects), so it might be useful to
plan for multi-stage approaches by use of interim data to
estimate key trial parameters and reassess the sample size.
• When there are only a small number of clusters available
for randomisation, the use of covariate constrained
allocation methods might be useful, given that baseline
imbalance between intervention and control groups might
be difficult to avoid with simple randomisation.
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Panel 1: Summary of the MORDOR trial: a cluster trial with planned interim analysis on mass distribution of azithromycin for
child mortality in sub-Saharan Africa
MORDOR is a placebo-controlled cluster trial that has been
undertaken in Malawi, Tanzania, and Niger, to evaluate the
efficacy of biannual mass distribution of oral azithromycin on allcause mortality for children aged 1–59 months.7 Before this study,
oral azithromycin had shown effectiveness against trachoma and
other infectious diseases, such as malaria, diarrhoea, and
pneumonia.15–20 Because mass distribution of azithromycin cannot
be tested in individually randomised clinical trials, due to risk of
contamination between groups, a cluster randomised trial design
was ideal to answer this research question.
The investigators of MORDOR prespecified plans for an interim
analysis for stopping the trial early on the basis of superiority
and futility. One interim analysis was implemented after
mortality data became available for a third of the person-years
in the study, with each country having contributed at least
6 months of follow-up for half or more of the clusters in each

country. An α value of 0·001 was used as the decision rule for
stopping the trial early for superiority, with an α value of 0·049
used to determine statistical significance at the final analysis.
The decision rule for stopping the trial early for futility was
prespecified as 20% or lower conditional power, to detect a
25% treatment effect. Because the decision rules for stopping
the trial early were not met, this cluster trial did not stop after
the interim analysis was done.
In the MORDOR trial, 1533 communities (clusters) were
randomly assigned to receive either mass distribution of oral
azithromycin or placebo on study completion,
with 190 238 children enrolled (323 302 person-years
monitored). This trial showed large mortality reduction benefits
with mass distribution of azithromycin; the azithromycin group
had a 13·5% (95% CI 6·7–19·8) lower child mortality risk
compared with the placebo.7

Panel 2: Summary of the PASTAL trial: an adaptive multiarm, multi-stage cluster trial for HIV testing and linkage to care
PASTAL is a phase 2 adaptive multiarm, multi-stage cluster trial
in Malawi that evaluated the effects on the uptake of HIV
testing and subsequent HIV services by male partners of
pregnant women accessing antenatal clinics.21,22 This trial
started with one control arm and five intervention arms. As the
standard of care, the pregnant women within clusters
randomised to the control group received a personalised
invitation letter to a male-friendly HIV clinic that was addressed
to their male partners, and this clinic would offer HIV testing,
linkage to care (if shown to be HIV-positive), and pregnancy
health education. The clusters randomly assigned to one
intervention group would receive the standard of care and
two self-test kits; those assigned to two other intervention
groups would receive standard of care, two self-test kits, and a
conditional financial incentive for the amount of either
US$3 (one group) or $10 (in the other group) for male partners
who self-tested and attended the HIV clinic. Another
intervention group received standard of care, two self-test kits,
and conditional lottery entry, with a 10% chance of
winning $30; and the final intervention arm received standard
of care, two self-test kits, and a telephone call reminder of their
clinical appointments.
Stopping the trial early was only considered for futility reasons,
and not for superiority. At the first stage, the outcomes
reported in each intervention group were compared with the
control group, and the intervention group was considered to be
dropped from the trial if the pairwise comparison showed a
p value that exceed 0·20. An independent data safety

cluster trials implemented across key global health
research areas, such as maternal, newborn, and child
health (MNCH), malaria, and water, sanitation, and
hygiene (WASH), to assess the current cluster trial
e702

monitoring board used this p-value threshold and
considerations of cost and safety to remove intervention
groups after the interim analysis at the first stage. The data
safety monitoring board stopped the interventional approach
that included a conditional lottery entry after the interim
analysis showed a p value of 0·211. The intervention that
consisted of standard of care and self-test kits only was
continued to the second stage, despite meeting the threshold
for stopping, due to the local policy makers wanting to test this
approach in the subsequent stage. In addition to stopping the
trial early, sample size reassessment was used to re-calculate the
sample size required for the second (final) stage of the trial. The
empirical estimates from the interim analysis were
used to re-calculate the sample size required under the
constraints of 10% family-wise type I error rate and
80% statistical power.
At the end of the trial, there were 71 antenatal clinics (clusters)
involved, with 2349 women randomly assigned (six clusters per
arm in the first stage and seven clusters per arm in the second
stage, after dropping the arm with the lottery). Compared with
control clusters in which 17·4% of the male partners were tested
for HIV, a higher proportion of male individuals met the
primary endpoint in all intervention arms. For instance, among
the intervention arm with conditional financial incentives of $3
or $10, which had the largest effect sizes, higher adjusted risk
ratios of 3·01 (95% CI 1·63–5·57; for the $3 group) and 3·72
(1·85–7·48; for the $10 group) were found.

planning practices in LMICs. Lastly, we describe
examples of high-quality and innovative LMIC-based
cluster trials, (panels 1–3) and we outline alternative
approaches and supplementary methodologies to
www.thelancet.com/lancetgh Vol 9 May 2021
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cluster designs that can be used to improve their
efficiency.

Why cluster trials are often used in research set
in LMICs
Cluster trials can be useful in LMIC settings for several
reasons. Cluster randomisation can potentially reduce
treatment contamination between intervention and
control groups.4,10,27 For instance, clinical trials of
nutritional interventions that are set in small, rural
communities can appropriately and effectively use this
design, since masking of nutritional interventions at the
individual level might not be possible and treatment
contamination could occur by food sharing between
community members randomly assigned to different
groups. If participants were individually assigned to the
control group, they could potentially receive food
supplements intended for the intervention group,
resulting in a partial effect of the intervention in the
control group, with or without a lesser effect in the
intervention group. In such a scenario, an underlying
true effect of the nutritional intervention is less likely to
be detected or might be blunted. As a result, several
cluster trials have had notable successes at improving
health outcomes that would otherwise be difficult to
assess with individual RCTs. These (non-exhaustively)
include Ebola vaccination,28 hypertension management,29
and overall childhood mortality.7 In these cases, and
in many more, careful planning and consideration of
the research question and mechanistic principles of
treatment has led to improved understanding across
a multitude of diseases, particularly in resourceconstrained settings.
In such a scenario, unless the sample size calculation
accounts for contamination, the effect of the nutritional
intervention is unlikely to be detected with the collected
data. Increasing the degree of treatment contamination
can reduce the statistical power of a given two-arm
individual RCT (figure). Similar findings of the
substantial risk of false-negative results have been shown
in the literature.27,30
By contrast, if the intervention can be delivered at the
level of the individual, it might be preferable to conduct an
individual RCT with a larger sample size, rather than by
cluster randomisation.31 The delivery of an intervention at
an individual level is particularly appropriate in
circumstances in which there is only a modest risk of
contamination, there is a large intracluster correlation
(ICC), or the cluster sizes are large.27 Sample size
requirements to reach 80% statistical power with varying
degrees of treatment contamination for a two-arm
individual RCT and for a two-arm cluster trial without any
contamination are shown in the figure and appendix (pp
2–3). The sample size required for an individual RCT is
smaller than that for a cluster trial with a modest degree of
treatment contamination. For instance, when 15% relative
risk reduction is expected at a baseline event rate of 20%,
www.thelancet.com/lancetgh Vol 9 May 2021

Panel 3: The THRio study (NCT00107887): a stepped-wedge cluster trial for
tuberculosis screening and preventive therapy
The tuberculosis/HIV in Rio de Janeiro (THRio) study was a stepped-wedge cluster trial
that aimed to evaluate the role of staff training in tuberculosis screening, tuberculosis skin
tests, and use of isoniazid preventive therapy versus standard of care in HIV clinics in Rio
de Janeiro, Brazil.23–26 Of the 29 HIV clinics (clusters) enrolled in this stepped-wedge trial,
two (7%) clinics were randomly assigned to the intervention group every 2 months
between September, 2005, and August, 2009. A coefficient of variation of 0·2 for
tuberculosis incidence rates was used to calculate the sample size, assuming a control
event rate of 3·65 events per 100 person-years and a 40% reduction in treatment effect
size (ie, of 2·20 events per 100 person-years in the intervention group) to reach a 5% type
I error rate and 80% statistical power. The primary analysis used an intention-to-treat
analysis, including all patients who were eligible to receive the tuberculosis skin test or
isoniazid preventive therapy (n=12 816 patients).
Compared with the control, the intervention showed an adjusted hazard ratio of 0·73
(95% CI 0·54–0·99) for tuberculosis incidence and an adjusted hazard ratio of 0·69
(0·57–0·83) for the composite outcome of incidence of and death from tuberculosis (with
adjustments made for age, sex, use of highly active antiretroviral therapy at baseline, and
time-varying CD4 concentration). Additionally, the rate of tuberculosis skin testing
showed an improvement from 19 events per 100 person-years observed during the
control period to 59 events per 100 person-years in the intervention period, and the rate
of isoniazid preventive therapy improved from 36 events per 100 person-years to
144 events per 100 person-years between the control and intervention periods.

an individual RCT without contamination requires a
sample size of 2069 per trial arm, compared with 2855 in
a cluster trial. The individual RCT is more efficient than a
cluster trial, as long as treatment contamination is
below 18%. The contamination threshold can increase
with larger cluster sizes or ICCs, or both, when treatment
effects are larger.

External validity
Another reason for the popularity of cluster trials
over individual RCTs is the perceived improved external
validity (or generalisability).4,32 This perception of
improved external validity is particularly prevalent when
interventions engage large cluster groups, such as
health districts. Global health research often aims to be
pragmatic, to answer whether interventions can work
under real-world conditions, and to be applicable to a
diverse population.33,34 Many health challenges in LMIC
contexts are well addressed by these aims. Cluster
trials provide a unique approach in infectious disease
interventional research, facilitating assessment of
population-level efficacy in the presence of herd effects.
Scaling of interventions is also reported as a benefit
of cluster trials. For instance, trials of interventions
administered at the community level more closely
resemble how a scaled intervention would be distributed
logistically. Further, cluster trials frequently cover the
entire community to provide a better estimate of group
benefit. A successful example of a community-based
scale-up interventional trial is the Control of Blood
e703
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Figure: Effects of treatment contamination on statistical power of a two-arm individually randomised
clinical trial assessing a dichotomous outcome and on the sample size required for 80% power
(A) Effect of treatment contamination on power of individual randomised clinical trials. (B) Sample size per trial arm
required for 80% power in an individual randomised clinical trial, with contamination (solid lines) and the degree of
contamination in an individual randomised clinical trial that requires a sample size identical to that of a cluster trial
without contamination (dashed lines) shown. Detailed assumptions are provided in the appendix (pp 2–3).
See Online for appendix

Pressure and Risk Attenuation study, set in Bangladesh,
Pakistan, and Sri Lanka, which was a multi-part
intervention delivered by community health workers to
manage hypertension. A strength of this study was that
the programme was focused on outreach by community
health workers rather than on guiding communities to
treatment centres and other settings outside of their
communities.29
Many individual RCTs are carried out with specific types
of patients under controlled conditions, with strict
inclusion and exclusion criteria (mechanistic individual
RCTs) for improved internal validity, but often this internal
validity is achieved at the expense of external validity
(explanatory trials). This type of trial design has been
criticised for not reflecting real-world conditions and
having unrealistic clinical populations, leading to poor
external validity.35–37 As such, evidence from cluster trials is
appealing to policy makers because their implementation
can more accurately reflect the real-world roll-out of novel
interventional strategies. However, related approaches,
such as pragmatic individual RCTs, can be carried out
with diverse groups of participants to evaluate the
effectiveness of interventions in real-life routine settings
without the use of cluster trial designs.36

Acceptability, adherence, and ethical considerations
Cluster trials are argued to have higher acceptability
by the communities receiving the interventions and
improved adherence to the allocated intervention
compared with individual RCTs.4,10 When treatment
group masking is not possible, individual randomisation
can create resentment among individuals randomly
assigned to the control group, particularly if the given
trial aims to evaluate the role of a desired intervention,
such as cash transfers.4 Cluster trials could be more
appropriate to evaluate these types of interventions
because it might be unfair and unethical for certain
individuals to receive financial aid while their peers
knowingly do not.4,38
e704

Cluster trials are conceptually able to improve
acceptability and adherence to an assigned intervention,
but these qualities are rarely assessed and reported
in cluster trial publications.32,39 Improved reporting on
such topics could strengthen these discussions. Some
shortcomings have been discussed with regard to
assessments of cluster trial acceptability from previous
work. In global health research, acceptability at the
community level is often assessed by village leaders, who
might not accurately speak on behalf of the individuals.38
This approach could affect the adherence of individual
members of the cluster, although it is important to note
that previous reviews of adherence in cluster trials
have indicated poor reporting of this characteristic,
complicating the interpretation of results.39

Practical advantages
Other reasons for the use of cluster randomisation
include practical advantages, such as administrative
convenience, lower implementation costs, and improved
acceptability and compliance compared with individual
RCTs.4,39,40

Trial planning challenges for cluster trials in
global health
A specific consideration in cluster trials is related to the
interplay between individuals and clusters. In cluster
trials, the responses of individuals within each cluster are
often correlated with respect to environmental, socio
economic, and other specified or non-specified prognostic
factors.40 This correlation leads to an increase of withincluster correlation and between-cluster variability in
the health outcomes concerned.4 In turn, the overall
variability of the observed treatment effects is inflated,
resulting in statistical inefficiency that might require a
much larger sample size compared with individual RCTs.41
Cluster trials that fail to account for the effects of clustering
in the analysis will result in inflated type I error rates.10,14
As such, it is vital to emphasise the importance of
including these characteristics in any statistical analysis
plan and subsequent publication. There is often a
misunderstanding among investigators and funders that
cluster trials facilitate enrolment of a larger number of
participants (more than 1000) than individual RCTs and
that these large sample sizes therefore might be more
representative or provide better precision.42,43
The effects of clustering on the sample size can be
expressed through the design effect, a statistical measure
of relative inflated variance due to cluster randomisation.4
For instance, a cluster trial with a design effect of 3 would
require triple the sample size of an individual RCT.
Calculating the design effect requires an estimated value
of the ICC or coefficient of variation. ICC measures the
similarity of the individual responses from within the
cluster, compared with the responses from different
clusters.4,44,45 As the ICC value decreases, so does the
required sample size for statistical power.45,46 The
www.thelancet.com/lancetgh Vol 9 May 2021
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coefficient of variation (a standardised measure of the
between-cluster variance) can also be used to express
the effects of clustering to calculate the sample size of
cluster trials, and is directly related to the sample size.4
For both cluster trials and individual RCTs, investigators
must prespecify characteristics such as effect sizes
and loss-to-follow-up rates. Prespecification of trial
parameters is an added challenge in cluster trials because
entire clusters might be lost to follow-up, and it might be
difficult to make such assumptions at the start of the
study. Availability of a sampling framework (the existing
number of clusters to choose from) for randomisation
and the size of the cluster all add to the complexity of
sample size calculation when compared with individually
randomised trials.47 As such, pretrial activities assessing
the true number of available clusters, running scenario
analyses, interim evaluations and, where appropriate,
clinical trial simulation can assist in developing
contingency plans for these challenges.

Number of clusters randomised within the trial
Knowledge of the number of clusters available for
randomisation is important for trial planning for a
multitude of reasons. Randomisation might help to
ensure that there is balance in observable and nonobservable prognostic factors between groups being
compared, but balance in prognostic factors is only
retained when there are a large number of clusters that
are being randomised. There are often geographical and
other practical constraints that limit the number of
clusters that can be enrolled in a given clinical trial,
particularly in LMICs. For instance, there might be only a
small number of hospitals in a region of interest, or there
might only be enough funding to enrol a small number
of clusters. The number of clusters should be adequate,
to minimise the chance of imbalance; although, this
number must also be considered in relation to the
potential for overpowering the trial.48,49 Notably, although
increased cluster numbers might generally improve
balance, specific plausible variables of interest (eg,
socioeconomic status and development parameters) must
also be adequately accounted for with increased cluster
numbers. As such, careful evaluation of cluster sizes and
local restrictions (eg, the total number of schools or
communities available) is essential for effective trial
planning.
Confounding resulting from imbalance can result in
inflated risks of false-positive and false-negative findings.
Although statistical techniques can adjust for baseline
covariates in cases of imbalance, these techniques still
require the availability of a relatively large number of
individual patient-level covariates, which might not be
available. The use of a large number of clusters is still
preferred, such that randomisation can ensure balance in
terms of both observable and non-observable factors
between groups being compared.50 Finally, it is important
to recognise that power in a cluster trial depends to
www.thelancet.com/lancetgh Vol 9 May 2021

a greater extent on the number of clusters than the cluster
sizes: a hypothetical cluster trial with hundreds of thousands
of participants but only a few clusters might never reach
80% statistical power, owing to the diminishing returns
that increasing participant numbers relative to increasing
cluster numbers provides for cluster trials.48

Cluster sizes and their variability
Cluster sizes and their variability are important limiting
factors for cluster trials. The cluster size (ie, the number of
participants per cluster) required to reach sufficient
statistical power depends on the number of clusters
available for randomisation. When the number of clusters
increases, fewer participants per cluster are ideal, and
when only a small number of clusters are available, a
larger number of participants per cluster is required.4,46
Although statistical power might be improved by
increasing the total sample size, increasing the sample
size can have diminishing returns on statistical power,
especially when the ICC is large.49 Increasing the sample
size becomes a particular challenge when communicating
the results of cluster trials. There is often a temptation to
relay the significance of a trial in relation to the total
sample size of the trial. In cluster trials, substantial
numbers of patients are often recruited, but each
individual’s respective contribution to the statistical power
of the trial is unclear without reference to the total cluster
size and associated variability.
In addition to cluster sizes, it is important to consider
the variability in sizes for trial planning because cluster
size variability can negatively affect the statistical
power.51,52 Compared with cluster trials with equal cluster
sizes, cluster trials with highly unequal cluster sizes
require larger sample sizes to reach the same statistical
power.46 In fact, the required sample size increases as the
cluster size variability increases, because smaller clusters
will have less precise treatment estimates than those
from larger clusters.46 Cluster size variability might cause
imbalances between intervention and control groups that
could be difficult to adjust for with the use of statistical
analyses.51 In instances for which allocation concealment
is not possible, cluster size variability and baseline
imbalance might result from selection or attrition biases,
or both.53
Cluster size variability is common in community trials
where, based on eligibility, there might be an underrecruitment of individuals in some of the clusters or an
over-recruitment in the other clusters, or both.51 If
recruitment is delayed due to under-recruitment in some
regions, there might be a perception that recruiting more
participants from other clusters will help to balance
the trial. However, this alteration might exaggerate the
cluster size variability or lower statistical power further
and introduce biases, affecting both the internal validity
and generalisability of the trial findings.51 The overall
effect of this variability on subsequent statistical power
and operational characteristics can be variable,54 and it is
e705
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frequently challenging to formally assess the effects of
variable cluster sizes, owing to poor reporting of key trial
characteristics within the literature.9

Anticipating the clustering effects
Anticipating the effects of clustering can be challenging.
There is often no accurate estimate of ICC, and as a result,
the ICC is often ignored or a nominal value (typically 0·05)
is used for sample size calculations of cluster trials.11 Even
with accurate assumptions about the underlying treatment
effects and baseline risks, which is also required for
individually randomised trials, a cluster trial might be
underpowered with an underestimated ICC assumption
or, on rare occasions in which the ICC is overestimated,
the trial can end up recruiting excessive numbers of
clusters and sample sizes. To facilitate future research
activities and improve the interpretation of cluster trials,
reporting of observed ICC values is crucial. Reporting of
ICC is currently recommended in the Consolidated
Standards of Reporting Trials extension for cluster trials
(item 17a), but this recommendation is limited to the
primary outcome only, and ICC is specific to each outcome,
creating challenges with interpreting secondary outcomes.9
Because a large number of clusters are usually required
to achieve balance between intervention and control
arms, cluster trials in global health research often involve
multiple geographical regions across several countries.
When carrying out a cluster trial across multiple regions,
there are frequently substantial disparities in disease
burden between geographical settings. These disparities
can contribute to high variability between different
clusters and thus inflate the ICC. For instance, recent
work has shown substantial subnational disparities in the
prevalence of childhood stunting in several African
countries, with national stunting prevalence varying by
more than five times between nearby countries.55
There can also be substantial disparities in disease
burden within a single country, making the implemen
tation of single-nation cluster trials difficult in global
health research. For example, in Rwanda, there are
disparities in the prevalence of childhood stunting
between different districts across Rwanda (appendix
p 4).56 Although the stunting prevalence in Kigali (the
capital city) is low (22%), the prevalence of stunting is
much higher in four nearby provinces (ie, the western,
northern, southern, and eastern provinces). Geographical
disparities in disease burden can pose challenges when
trying to estimate the clustering effects as part of trial
planning of cluster trials in global health research.
Another example of the influence of geography on trial
outcomes is cord cleansing with chlorhexidine, which in
settings of a high incidence of home-birth deliveries
(around 75%) showed marked improvements in neonatal
mortality.57 When repeated in settings of a high incidence
of facility-birth deliveries (around 65%), minimal
improvements were noted, emphasising the importance
of cluster selection.58
e706

Maintaining internal validity
As briefly mentioned, cluster trials are often preferred
in global health research for their pragmatism and
generalisability, but at a compromise of internal validity.4,42
Balancing for external validity and internal validity needs
careful consideration. Although selection bias is possible
in individual RCTs, such biases can be more problematic
for cluster trials because attrition bias can occur at both the
individual and cluster levels.42 For instance, for a hospitalbased cluster trial, doctors acting as recruiters for the
hospital might be less motivated to recruit patients if their
hospital was randomly assigned to the control group than
doctors in hospitals allocated to the intervention group.
There are several strategies to minimise selection bias
for cluster trials, covering both individual-level and clusterlevel selection biases.42,43,59 Bias from study recruiters can
be minimised by use of an independent recruiter who is
masked to group allocation. Selection bias at the individual
level can be minimised by identifying and obtaining
consent from participants before cluster randomisation,60
or by offering delayed assignment to the other group (eg,
at the end of the study).

Ethical challenges
In addition to the aforementioned statistical issues, cluster
trials can raise difficult ethical questions for global health
research. A useful resource for researchers interested in
these challenges is the Ottawa Statement on Ethical
Design and Conduct of Cluster Randomised Trials.61 In
essence, cluster trials share many ethical challenges with
individual RCTs, although there are several unique design
features which warrant a more detailed review.
In individual RCTs, obtaining informed consent from
each individual study participant is usually required;
however, in cluster trials, informed consent might only
be obtained from selected members of the community if
the interventions can only be administered at the
community level.38 The role of such community
gatekeepers in cluster trials is a contentious topic in
medical ethics; for further discussion, readers are
encouraged to review Gallo and colleagues’ work
reviewing this specific issue.62
For interventions that can be evaluated by use of
individual RCTs, it is important that these interventions
have already shown their clinical utility and pose minimal
risks to the population before being considered for cluster
trials, given that these designs often result in large
numbers of participants. Additionally, it is important to
consider the potential ethical issues of withholding a
given intervention from certain communities and not
others, because this can contribute to the perception of
health inequity among trial participants and between
communities.38 As data accumulate in a cluster trial, or if
policy changes occur during the implementation of the
trial, there might be a strong obligation to modify or even
stop the study if the study intervention is unsafe or
ineffective, or both.38
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All (n=80)

MNCH (n=23)

Malaria (n=32)

WASH (n=25)

Proportion of trials with binary or count outcome as the primary outcome

62 (78%)

10 (43%)

32 (100%)

20 (80%)

Binary or count baseline effect was >50% smaller than predicted

11/45 (24%)

1/9 (11%)

7/24 (29%)

3/12 (25%)

Binary or count treatment effect was meaningfully different to predicted value*

27/53 (51%)

7/10 (70%)

14/29 (48%)

6/14 (43%)

Intracluster correlation or coefficient of variation was meaningfully different to
predicted value†

9/13 (69%)

4/5 (80%)

5/6 (83%)

0/2 (0%)

Data are n (%) or n/N (%). MNCH=maternal, newborn, and child health. WASH=water, sanitation, and hygiene. *Observed effect of <25% relative risk reduction or <2% absolute
differences for binary outcomes. †A difference of >50% relative to the originally planned value, regardless of direction of effect. The substantially smaller denominator value is
because of the small (16%) number of trials that reported both a planned and an observed intracluster correlation or coefficient of variation.

Table: Assessment of sample size calculation practices for cluster trials in global health: baseline event rate, treatment effect size, and intracluster
correlation assumptions across MNCH, malaria, and WASH trials

Assessment of cluster trial planning practices in
global health
To provide some examples of cluster trial planning
practices in global health research set in LMICs, we did
a focused literature review of LMIC-based cluster trials
that have been published between Jan 1, 2010, and Nov 1,
2018 for three key areas of global health research:
MNCH, WASH, and malaria. We evaluated the cluster
trial planning practices in global health research set in
LMICs by assessing the reported assumptions used to
derive sample size estimations among the 80 eligible
cluster trials in these selected disease topics (table). The
search terms, eligibility criteria, and details of our
analytical approaches for this assessment are provided
in the appendix (pp 5–27).
Although not unique to cluster trials or global health
research, cluster trial sample size calculations are often
done with higher baseline event rates, overly optimistic
treatment effect sizes, and lower clustering effects than
those that are actually observed later. Among the cluster
trials on the topics of MNCH, WASH, and malaria, we
identified that a large proportion of these trials used
higher rates of baseline event rates and anticipated
treatment effects for sample size calculations than those
that were later actually observed. Of the 80 included
trials, 62 (78%) of the trials were undertaken with binary
or count data primary outcomes. Of the 80 trials assessed,
45 (56%) reported data on assumed baseline risks. Where
presented, 11 (24%) of 45 trials reported a baseline risk or
rate at least 50% smaller than anticipated. The proportion
of overestimates varied across the included topics, with
MNCH representing the lowest proportion (11%), and
malaria (29%) and WASH (25%) trials representing
similar proportions. Three (7%) of the 45 trials had
overestimated the baseline risk or rate during planning
by at least 50%.
In examining treatment effect sizes, we observed
that 27 (51%) of 53 of the included trials reported
overestimation of treatment effects, in which the observed
effect size was at least 50% smaller than the assumed
effect size for sample size calculations. Higher proportions
of overestimation (ie, an effect size less than 50% of the
assumed effect size) were noted in MNCH trials (70%)
www.thelancet.com/lancetgh Vol 9 May 2021

relative to malaria (48%) and WASH (43%) trials. It was
more difficult to assess the cluster trial planning practices
in terms of clustering effects because the ICC was often
inadequately reported. Of 80 cluster trials identified, only
13 trials (16%) reported on both planned and observed
ICC. Of the 13 trials that reported both planned and
observed ICCs, 9 (69%) noted a difference of 50% or
greater than assumed values. Overall, 8 (18%) of 45 trials
showed an overestimation of baseline effects at the same
time as an overestimation of treatment effects. Similarly,
12 (27%) of 45 trials reported overestimations of treatment
effects and either ICC or baseline effects.
There are many possible reasons for the high
frequency of erroneous assumptions used for cluster
trial planning in terms of baseline event rates, treatment
effects, or clustering effects. Erroneous assumptions
used, particularly for treatment effect sizes, might be
due to optimism held by the trial investigators.
Although we report on the widespread mismatch in
anticipated baseline event rates and treatment effects
relative to those that were later actually observed in the
global health cluster trials, this disparity was not
frequently discussed in the publications. One publication
noted that their substantially lower observed base event
rate for malaria prevalence was almost certainly due to a
drought that coincided with the initiation of their trial.63
Another malaria trial noted that stopping of one outcome
measurement of parasite detection was due to the low
event rate of parasite carriage in enrolled clusters,64
whereas two other trials noted that their planned sample
size was increased to retain appropriate statistical
power.65,66

Alternative approaches and designs for cluster
trials in global health
Interim evaluations

Cluster trials usually have a single-stage approach with a
fixed trial design, in which all clusters are enrolled and
randomised simultaneously and then observed for a
fixed duration. Instead of using a single-stage approach,
it might be beneficial to use a multi-stage approach, in
which interim data are used to estimate the key trial
parameters and calculate the sample size again (sample
e707
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size reassessment).67 To determine the timing of the
interim analysis, a sufficient number of observations
from the enrolled clusters are required for a reliable
estimate of the ICC at the interim analysis.68
For instance, if a sample size reassessment shows that
the new requirements in sample size or in the number
of clusters exceed what is realistically feasible, a decision
to stop the trial might be considered. The use of a multistage approach with preplanned interim evaluation
plans can represent an appealing mechanism to
minimise the risks of false-negative findings for cluster
trials in which uncertainty exists over the planned trial
parameters.69 High-profile cluster trials have already
integrated such methodologies, such as early stopping
rules for efficacy and futility,7 as well as preplanned rules
for stopping of treatment arms in isolation for multiarm
trials.70

Statistical methods for imbalance
It is often assumed that randomisation can remove
selection bias and produce groups that are comparable in
terms of both measurable and unmeasurable factors.
However, in cluster trials, this assumption might not
hold true, especially when there is a low number
of clusters available. The potential risk of baseline
imbalance between the intervention and control groups
can be substantial when there is a small number of
clusters available.40 If data are available for important
cluster-level or individual-level covariates, covariateconstrained randomisation could be a useful method to
prevent imbalance in studies for which there is only a
small number of clusters.71
In covariate-constrained randomisation, investigators
determine criteria for balance across key baseline
covariates of interest. All possible configurations of
allocations of participating clusters can then be
generated to subsequently be narrowed down to a
smaller list of potential allocations by use of the
prespecified criteria for balance. Then, the actual
allocation would be chosen randomly from this
narrower list to maintain an appropriate level of
randomness in this selection process. When using
covariate-constrained randomisation, it is important to
prespecify the key covariates and the criteria for balance
before generating all possible allocation schemes. It is
also important not to apply overconstraint through
strict balancing requirements because this scenario
might result in very few possible allocations and, thus,
not represent true randomisation.71 Covariates used in
the constrained randomisation should be adjusted for
in the statistical analyses, to avoid inflation of type I
error rates.72

Stepped-wedge designs
A stepped-wedge design is a type of cluster trial design in
which all clusters start in the control condition but
gradually cross over to the intervention condition, in
e708

randomised sequence, until every cluster included in the
trial has received the intervention of interest.73 This design
differs from the conventional parallel design that is most
often used in cluster trials because, in parallel design,
clusters are randomly assigned to intervention or control
groups; not all clusters receive the intervention of interest
before the cluster trial with a parallel design is completed.73
Stepped-wedge designs can help to minimise some of
the drawbacks of parallel arm designs under select
circumstances. For instance, stepped-wedge designs
might be useful when there is only a small number of
clusters available. Stepped-wedge designs can often reach
the same statistical power as the parallel cluster trial
design but with fewer clusters, particularly when ICC
values are greater than 0·03.73,74 The reason stepped-wedge
designs might require fewer clusters is because each
cluster is exposed to both control and intervention
conditions; hence, the estimation of treatment effects in a
stepped-wedge trial can benefit from the use of withincluster comparisons. For example, using the results of a
previous cluster trial,75 Hooper and Bourke74 have shown
that a stepped-wedge design consisting of two, three, or
four regular intervals (the so-called steps), in which a
group of clusters are randomised to cross from the control
to the intervention, reduced the required number of
clusters to reach appropriate statistical power by 23%,
54%, and 66%, respectively. Another advantage of steppedwedge designs is less sensitivity of statistical power to the
ICC value. Although the statistical power is reduced in
both parallel and stepped-wedge trial designs when an
underestimated ICC value is used for sample size
calculation, the statistical power for the stepped-wedge
design is less affected than that of the parallel design.73
However, stepped-wedge cluster trials increase statistical
complexities compared with parallel cluster trials in that
correlation coefficients are more complex: not only do
correlations within the same cluster need to be accounted
for, correlations in repeated measures from the same
cluster over time also need to be factored in.
Although stepped-wedge trials offer promise when high
numbers of individuals per cluster are available, these
trials do have drawbacks. Even though increased steps can
provide improved statistical properties, this approach also
requires more measurements (and, as such, a potentially
longer trial duration) per cluster compared with parallel
designs.76 As such, there is an important need during trial
planning to balance the number of steps and associated
sample size reduction against increased operational costs
and trial duration with increased numbers of observations,
and whether there are any associated ethical implications
with this. The associated operational complexity of
coordinated calendar timing for stepped-wedge designs
must also not be underestimated. Potentially as a
consequence of this underestimation, authors have
previously noted that approximately half of stepped-wedge
trials failed to reach their planned sample size and
implementation schedules.77
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Conclusion
Evaluating whether interventions have an effect at the
population level is challenging. The most commonly
applied method for evaluating population-level effects—
ie, the cluster trial—has complications that can be
difficult to overcome. When carried out successfully,
these trials represent a unique and powerful investi
gational tool, but careful considerations should be made
ahead of their implementation. Cluster trials are typically
much larger than individual RCTs, so these trials require
considerably larger financial resources, posing challenges
for LMICs and research funding bodies that are already
stretched. More rigorous pretrial estimation processes,
alongside integration of novel trial methodologies, might
reduce the prevalence of these problems and minimise
the number of participants recruited, the money spent,
and the time lost on trials that do not have the necessary
characteristics to draw meaningful conclusions.
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